Upfront Surgery Versus NeoAdjuvant Chemotherapy Followed by Surgery for Resectable Advanced Gastric Cancer: SNAC Study
NCT06472063 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 684
Last updated 2024-06-24
Summary
Based on the concerns about the actual low strength of evidence of the efficacy of NAC on survival of proper gastric cancer treated with adequate D2 gastrectomy as compared to the results of optimal upfront surgery (S), and considering the actual difficulties of additional RCTs, the aim of this study is to assess the non-inferiority of upfront surgery alone with optimal D2 dissection compared to NAC regimens followed by surgery. Methods: This is a nationwide Multicenter observational retrospective study with matched comparison of two therapeutic strategies (NAC vs S). We will include patients with cT\>2, every cN M0, or with every T and N+ M0, histologically proven adenocarcinoma of the stomach, submitted either to pre- or peri-operative treatment and D2 gastrectomy or to upfront D2 gastrectomy, between January 2012 and December 2019, followed by adjuvant treatment when recommended.
All patients matching the inclusion/exclusion criteria will be registered into the study and classified into one of the two arms: a, patients who underwent pre- or perioperative treatment and D2 gastrectomy (NAC) or b, patients submitted to upfront D2 gastrectomy (S). Given the results reported in the "FLOT" trial, a 3-years OS of 55% in the control arm (NAC) was assumed. Three-year OS in the experimental arm (S) was assumed to be 47.4% under the null hypothesis of inferiority and 55% under the alternative hypothesis of non-inferiority. A sample size of 684 patients (342 in each arm) achieves 80% power to detect a non-inferiority margin Hazard Ratio of 1.25
Conditions
Interventions
- OTHER
-
pre- or perioperative treatment and D2 gastrectomy
pre- or perioperative treatment and D2 gastrectomy
Sponsors & Collaborators
-
Azienda Ospedaliera Universitaria Senese
collaborator OTHER -
IRCCS Ospedale San Raffaele
collaborator OTHER -
Federico II University
collaborator OTHER -
Azienda Ospedaliero-Universitaria di Parma
collaborator OTHER -
Azienda Ospedaliero Universitaria Policlinico Modena
collaborator OTHER -
Istituti Tumori Giovanni Paolo II
collaborator NETWORK -
Fondazione IRCCS Policlinico San Matteo di Pavia
collaborator OTHER -
ASST Grande Ospedale Metropolitano Niguarda
collaborator OTHER -
Azienda Ospedaliera Sant'Anna
collaborator OTHER -
Ospedale di Circolo - Fondazione Macchi
collaborator OTHER -
Ospedale San Donato
collaborator OTHER -
Government hospital in Forlì, Italy
collaborator OTHER -
Istituti Ospitalieri di Cremona
collaborator OTHER -
Azienda Ospedaliero-Universitaria Careggi
collaborator OTHER -
Azienda ULSS di Verona e Provincia
collaborator OTHER -
Azienda Ospedaliera di Perugia
collaborator OTHER -
A.O. Ospedale Papa Giovanni XXIII
collaborator OTHER -
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
collaborator OTHER -
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
collaborator OTHER -
Provincia Autonoma di Trento
collaborator OTHER_GOV -
University of Florence
collaborator OTHER -
Ospedale M. Bufalini Cesena
collaborator OTHER -
Azienda Ospedaliera di Padova
collaborator OTHER -
Ospedale Guglielmo da Saliceto, Piacenza
collaborator UNKNOWN -
Azienda Ospedaliera San Gerardo di Monza
collaborator OTHER -
A.O.U. Città della Salute e della Scienza
collaborator OTHER -
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
collaborator OTHER -
Ospedale Santo Stefano
collaborator OTHER -
Policlinico Abano Terme
collaborator OTHER -
Istituto Europeo di Oncologia
collaborator OTHER -
Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona
collaborator OTHER -
Humanitas Hospital, Italy
collaborator OTHER -
San Luigi Gonzaga Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-09-22
- Primary Completion
- 2023-08-30
- Completion
- 2024-09-30
Countries
- Italy
Study Locations
More Related Trials
-
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
NCT04931420 ·Status: WITHDRAWN ·Phase: PHASE2
-
Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2)
NCT00147147 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy
NCT06277453 ·Status: ACTIVE_NOT_RECRUITING
-
Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
NCT02845986 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas
NCT04268121 ·Status: RECRUITING ·Phase: PHASE2
-
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
NCT04447352 ·Status: RECRUITING ·Phase: PHASE3
-
Perioperative Chemoradiotherapy for Potentially Resectable Gastric Cancer
NCT00420394 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of 5-FU Versus MTX+5-FU in Gastric Cancer With Peritoneal Metastasis
NCT00149201 ·Status: COMPLETED ·Phase: PHASE3
-
Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer
NCT01876927 ·Status: COMPLETED ·Phase: PHASE2
-
A Study on the Potential Benefit of Neoadjuvant Therapy for AGC Patients
NCT05442138 ·Status: UNKNOWN
-
Compare Different Response Evaluations to Neoadjuvant Chemotherapy for Gastric Cancer
NCT02179463 ·Status: UNKNOWN
-
Comparison of Long-term Outcomes Between Upfront Surgery and Neoadjuvant Therapy Followed by Surgery in Patients with Node-Negative Gastric Cancer
NCT06673472 ·Status: COMPLETED
-
Feasibility Trial of Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer
NCT01381913 ·Status: COMPLETED
-
Phase III Study OF the Gastric Surgery on Advanced Stage Gastric Cancer
NCT00260884 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer
NCT01815853 ·Status: COMPLETED ·Phase: PHASE3
-
PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy
NCT03013010 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial to Evaluate Para-aortic Lymphadenectomy for Gastric Cancer
NCT00149279 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
NCT02005484 ·Status: TERMINATED ·Phase: PHASE2
-
Gastric Cancer Survival Without Chemotherapy
NCT05125614 ·Status: COMPLETED
-
The Effect of Neoadjuvant Chemotherapy on Locally Advanced Gastric Cancer
NCT01444755 ·Status: UNKNOWN
-
A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen
NCT01070290 ·Status: WITHDRAWN ·Phase: PHASE2
-
Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG
NCT04062656 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Chemotherapy Plus Chemoradiation in Patients With Potentially Resectable Gastric Carcinoma
NCT02024217 ·Status: UNKNOWN ·Phase: PHASE2
-
Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer
NCT01379482 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Gastric Cancer
NCT01305993 ·Status: UNKNOWN ·Phase: PHASE2